More than 125 international academics and industrials from 27 different countries will be joining Targeting Phage Therapy 2023 on June 1-2 in Paris. During Targeting Phage Therapy 2023, 50+ communications will be presented in the form of major talks, short orals, and posters.
Among the speakers
Targeting Phages 2023 will address how phages play a strategic role to combat infection and antibiotic resistance, but also to modulate gut microbiota. Phage enthusiasts and experts will be presenting their latest data and innovations.
Domenico Frezza, University of Roma Tor Vergata, Italy
“Phage Therapy: Vision, Gaps and Evolution”
Martha Clokie, University of Leicester, United Kingdom
“Challenges and Opportunities for Bacteriophage Therapy”
Marvin Edeas, Université de Paris, INSERM 1016, Institut Cochin, France
“Introduction to Bacteriophages & Microbiota: On the Way to a Medical Revolution”
William Summers, Yale University, USA
“Historical Reflections of the Trials and Tribulations of Phage Therapy: 1930-1950”
Mzia Kutateladze, Eliava Institute of Bacteriophage, Georgia
“Bacteriophage Therapy: From Soviet Clinical Experience to Current Activities at the Eliava Institute”
Anders S. Nilsson, Stockholm University, Sweden
“Novel Computer Program for Modelling Bacteriophage Infection Kinetics”
Jean-Paul Pirnay, Queen Astrid Military Hospital, Belgium
“Bacteriophages: It’s a medicine, Jim, but not as we know it”
Cara Fiore, Food and Drug Administration (FDA), USA
“The Regulation of phage therapy applications in humans in the USA”
Anthony Maresso, TailΦr Labs, Baylor College of Medicine, USA
“Phage 3.0: Spotlighting the Viral Genosphere for Drug Discovery, Biotechnology, and Novel Biological Functions”
Martial Marbouty, Institut Pasteur, France
“Phage-Bacteria Interaction Network in Human Intestinal Tract”
Aleksandra Petrovic Fabijan, Westmead Institute for Medical Research, Australia
“Therapeutic Monitoring of Phage Therapy”
Austen Terwiliger, TailΦr Labs, Baylor College of Medicine, USA
“Retrospective outcomes of personalized phage therapy for ESKAPE pathogen”
Tristan Ferry, Hospices Civils de Lyon, France
“The Use of Bacteriophage Therapy for Complex Bacterial Infections: the PHAGEinLYON Experience”
Mariagrazia Di Luca, University of Pisa, Italy
“Phage-based drugs for the treatment of biofilm-associated infections”
Ryszard Międzybrodzki, Hirszfeld Institute of Immunology and Experimental Therapy PAS, Poland
“Phages in the Medical Research Activity in Poland”
Anna Pistocchi, Università degli Studi di Milano, Italy
“Investigating the Therapeutic Potential of Phages as Antibacterials and Immunomodulators in a Zebrafish Model of Cystic Fibrosis”
Rodrigo Ibarra Chavez, University of Copenhagen, Denmark
“Phage-inducible Chromosomal Islands Promote Genetic Variability by Blocking Phage Reproduction“
Lilian Musila, U.S. Army Medical Research Directorate, Kenya
“Potential of Therapeutic Phages to Combat MDR ESKAPE Pathogens in Developing Nations”
Noemi Poerio, University of Rome Tor Vergata, Italy
“A Novel Combined Host- and Pathogen-Directed Therapeutic Approach to Fight Infections by MDR- Klebsiella pneumoniae”
Jolien Onsea, KU Leuven, Belgium
“The Use of Bacteriophage Therapy for Difficult-to-Treat Musculoskeletal Infections: the PHAGEFORCE Experience”
Mina Pastagia, Armata Therapeutics, USA
"Safety, Pharmacokinetics, and Antibacterial Activity of AP-PA02 Multi-phage Cocktail in Patients with Cystic Fibrosis and Chronic Pulmonary Pseudomonas aeruginosa Infection (SWARM-P.a. Clinical Trial)"
Alexander Sulakvelidze, President and CEO of Intralytix, Inc., USA
“Modern Approaches for Optimizing Therapeutic Phage Preparations”
David Jernigan, PhagenCorp, LLC, USA
“Inducing Native Phages from the Human Virome to Address Targeted Infections”
Pranav Johri, Founder of Vitalis Phage Therapy, India
“From Patient to Advocate – Introducing Phage Therapy to India”
Jessica Sacher, Cofounder of Phage Directory, Australia
“Scaling Phage Therapy, Starting with Phage Australia”
“Combined Therapies of Wound Infections with Phages/MSCs Aggregates”
Who is Attending Targeting Phage Therapy 2023?
Industrial participants: Armata Pharmaceuticals (USA), Cellexus (UK), Aparon (UK), AusHealth (Australia), Biochimpharm JSC (Georgia), BIOCODEX (Paris), BIOMERIEUX SA (France), COBIK (Slovenia), ERYTECH Pharma (France), Intralytix, Inc. (USA), MB Pharma s.r.o. (Czech Republic), Optipharm Inc. (Republic of Korea), PhagenCorp, LLC (USA), Phagos (France), Pherecydes Pharma (France), Proteon Pharmaceuticals S.A. (Poland), Resistell (Switzerland), Rime Bioinformatics (France), SET Medikal (Turkey), Vitalis Phage Therapy (India)…
Academic participants: Agricultural University of Athens, Chungnam Natl. Univ., Comenius University, Consejo Superior de Investigaciones Científicas, Corpo De Bombeiros Militar Do Amazonas, CY Paris Cergy Université, Deutsches Zentrum für Infektionsforschung, Eliava Institute of Bacteriophages, microbiology and virology, Eötvös Loránd University, Food and Drug Administration (FDA), Fundação Universidade Aberta Da Terceira, Fundación AZTI, Geneva University Hospitals, German Center for Infection Research, Hirszfeld Institute of Immunology and Experimental Therapy, Hôpitaux Unversitaires de Genève, Hospices Civils de Lyon, IDADE, IIBR, Ilia state university, Instituto de Biología Integrativa de Sistemas (I2SysBio) Universitat de València-CSIC, Israel Institute for Biological Research, Istanbul University, KU Leuven, Laboratoire M2iSH, Masaryk University, Max Planck Institute for Medical Research, Medical center Francesc Macia, MPI, National Taiwan University, North-West Unversity, Pharmabiotic Research Institute, Phage Directory, Prof. Waclaw Dabrowski Institute of Agricultural and Food Biotechnology - State Research Institute, Queen Astrid Military Hospital, Stockholm University, The Chinese University of Hong Kong, Umeå University, Universidade de Aveiro, Universidade Federal de São Paulo, Università degli Studi di Milano, Università del Piemonte Orientale "A. Avogadro", Universitat de València, Université Clermont Auvergne, University College London, University Hospital Regensburg, University of Copenhagen, University of Edinburgh, University of Exeter, University of Leicester, University of Milano, University of Pisa, University of Rome Tor Vergata, University of Verona, US Army Medical Research Directorate – Georgia, Victor Babeş University of Medicine and Pharmacy, Westmead Institute for Medical Research, Yale University, TiHo Hannover…
PHAGE Therapy, Applications, and Research Journal is the Official Partner of Targeting Phage Therapy 2023
The Editor in Chief, Prof. Martha Clokie, will be attending the conference as a major speaker. You have the chance to discuss about future collaboration.
Targeting Phage Therapy 2023: 10 Minutes to Convince
Targeting Phage Therapy 2023 will dedicate a session for the latest research and innovations in the field of phages and phage therapy. You will have 10 minutes to convince and present your work. You still have time to submit your abstracts or innovations.
Among the companies that will exhibit their innovations during Targeting Phage Therapy 2023: Armata Pharmaceuticals and Cellexus.
Targeting Phage Therapy 2023 Media Partners: Phage Directory and Bacteriophage.news.